

510(k) Summary**General Information**

Classification

Class II

Trade Name

VariCath™ Peripheral Infusion Catheter

Submitter

VeinRx Inc
8200 N.W. 27th Street
Suite 102
Miami, FL 33122

DEC 9 2007

305-716-7005

Contact

Aaron Perlmutter, MD
Vice President – Medical & Scientific Affairs**Intended Use**

The VariCath Peripheral Infusion Catheter is intended for the infusion of physician specified fluids, including thrombolytics, into the peripheral vasculature.

Predicate DevicesInfusionCath Peripheral Infusion Catheter
Manufactured by VeinRx, Inc.

K041517 & K052738

Device Description

The VeinRx VariCath Peripheral Infusion Catheter is comprised of a distal occlusion balloon, a variable infusion length catheter body with infusion holes, and a proximal trifurcated Luer connection hub. The trifurcated hub allows connection to three main systems of the device. The VariCath is packaged inside a protective tube mounted on a card and placed in a sealed protective pouch.

Materials

All materials used in the manufacture of the VariCath Peripheral Infusion Catheter are suitable for this use and have been used in numerous previously cleared products.

Testing Summary

The VariCath Peripheral Infusion Catheter was tested in the same manner as the InfusionCath Peripheral Infusion Catheter. All components, subassemblies, and/or full devices met the required specifications for the completed tests.

Summary of Substantial Equivalence

The VariCath Peripheral Infusion Catheter is equivalent to the predicate product, the InfusionCath Peripheral Infusion Catheter. The indications for use, function, methods of manufacturing, and materials used are substantially equivalent. VeinRx, Inc. believes the VariCath Peripheral Infusion Catheter is substantially equivalent to existing legally marketed devices



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

DEC 8 0 2007

VeinRx Inc.
c/o Mr. Gregory J. Mathison
Regulatory Affairs
8210 NW 27th Street
Miami, FL 33122

Re: K073400
Trade/Device Name: VariCath Peripheral Infusion Catheter
Regulation Number: 21 CFR 870.1210
Regulation Name: Continuous Flush Catheter
Regulatory Class: Class II (two)
Product Code: KRA
Dated: November 26, 2007
Received: December 4, 2007

Dear Mr. Mathison:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Page 2 - Mr. Gregory J. Mathison

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): This application K073400

Device Name: VariCath Peripheral Infusion Catheter


Indications for Use: The VariCath Peripheral Infusion Catheter is intended for infusion of physician specified fluids, including thrombolytics, into the peripheral vasculature.

Prescription Use X OR Over-The-Counter Use _____

(Per 21 CFR 801.109) (Optional Format 1-2-96)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


Division Manager
Division of Cardiovascular Devices
510(k) Number K073400